AbCellera (ABCL) announced that it has entered into a strategic collaboration with Incyte (INCY) to discover and develop therapeutic antibodies in oncology. Under the financial terms of the agreement, Incyte has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and regulatory milestone payments and royalties on net sales of products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABCL:
- AbCellera price target lowered to $12 from $20 at Benchmark
- AbCellera reports Q2 EPS (11c), consensus (13c)
- AbCellera says U.S. Patent Office denies Berkeley Lights’ request for rehearing
Questions or Comments about the article? Write to editor@tipranks.com